TUKYSA Added to First-Line Maintenance Therapy Extends Median ...
5 days ago · TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain …
UCI 22-222: A Phase III, Mutlicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor …
Adding tucatinib to first-line maintenance therapy delays disease ...
5 days ago · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
SABCS 2025 News: Updated EMBER-3 Efficacy Results for Imlunestrant …
3 days ago · Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant-based regimens as all-oral, chemotherapy-free treatment options for endocrine …
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment …
15 hours ago · The expanded approval for ENHERTU in the U.S. enables its use earlier as part of a combination regimen in the first-line setting of patients with HER2 positive metastatic breast cancer.
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2 ...
13 hours ago · The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki; AstraZeneca and Daiichi Sankyo) plus Perjeta (pertuzumab) for the first-line treatment of adults with unresectable or …
1 in 4 metastatic breast cancer patients treated with - GlobeNewswire
6 days ago · “The latest MONALEESA analysis shows that 1 in 4 patients with metastatic disease remained progression-free for four years or more.
Orange County, CA - UCI Health
Oct 17, 2024 · Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with …
Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic ...
4 days ago · One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to pooled MONALEESA data …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali ...
6 days ago · Metastatic breast cancer is cancer that has spread beyond the breasts to other parts of the body. Long-term progression-free survival benefit with Kisqali was observed in patients regardless of …